ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1652

The Hidden Impact of Hyperuricemia on Immune Cell Dysfunction
Abstract Number: 0169

The High Disease Burden of Connective Tissue Disorder-Interstitial Lung Disease in the USA Demonstrates an Unmet Need for Earlier Diagnosis and Treatment
Abstract Number: 0125

The IFN Signature is Less Pronounces in Primary Antiphospholipid Syndrome Compared with other Systemic Autoimmune Diseases
Abstract Number: 1342

The Impact of Age on Health-Related Quality of Life in Patients With Rheumatoid Arthritis Compared to Population Controls: A Cross-Sectional Analysis
Abstract Number: 1636

The Impact of Arthritis on Self-Management Activities of West Virginia Adults with Type 2 Diabetes During the COVID-19 Pandemic
Abstract Number: 1409

The impact of depression in axial spondyloarthritis: Epidemiological insights from the Ankylosing Spondylitis Registry of Ireland (ASRI)
Abstract Number: 0460

The Impact of Early and Artificial Menopause on Dementia Risk Among Women with Rheumatoid Arthritis
Abstract Number: 1539

The Impact Of Interferon Signature On Anifrolumab Efficacy And Safety In Systemic Lupus Erythematosus: A Systematic Review And Meta-analysis
Abstract Number: 1136

The Impact of Iron Overload and HFE Genetic Mutations on Joint Disease in Haemochromatosis: Data from the Haemochromatosis Arthropathy Inception Cohorts
Abstract Number: 2225

The Impact of Pregnancy Planning on the Prevalence of Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Retrospective Study from Three Japanese Tertiary Referral Centers
Abstract Number: 1642

The Impact of Secukinumab on Bone Density in Patients with Ankylosing Spondylitis: A 1-Year Retrospective Study
Abstract Number: 2606

The Impact of Social Media and Artificial Intelligence on Illness Perception and Treatment Adherence in Patients with Rheumatic Diseases
Abstract Number: 0415

The Impact of Social Vulnerability Index Scores in Pediatric Uveitis
Abstract Number: 1884

The Importance of Adherence to Dietary Recommendations for Rheumatoid Arthritis Risk May Be Greater in Younger Individuals – Results from a Nested Case-Control Study
Abstract Number: 1906

The incidence and mortality of connective tissue diseases in England: a population-level cohort study from 2012 to 2023

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].